These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35740681)

  • 1. A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources.
    Xiang H; Zhang L; Bu F; Guan X; Chen L; Zhang H; Zhao Y; Chen H; Zhang W; Li Y; Lee LJ; Mei Z; Rao Y; Gu Y; Hou Y; Mu F; Dong X
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes.
    Chong C; Müller M; Pak H; Harnett D; Huber F; Grun D; Leleu M; Auger A; Arnaud M; Stevenson BJ; Michaux J; Bilic I; Hirsekorn A; Calviello L; Simó-Riudalbas L; Planet E; Lubiński J; Bryśkiewicz M; Wiznerowicz M; Xenarios I; Zhang L; Trono D; Harari A; Ohler U; Coukos G; Bassani-Sternberg M
    Nat Commun; 2020 Mar; 11(1):1293. PubMed ID: 32157095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.
    Ouspenskaia T; Law T; Clauser KR; Klaeger S; Sarkizova S; Aguet F; Li B; Christian E; Knisbacher BA; Le PM; Hartigan CR; Keshishian H; Apffel A; Oliveira G; Zhang W; Chen S; Chow YT; Ji Z; Jungreis I; Shukla SA; Justesen S; Bachireddy P; Kellis M; Getz G; Hacohen N; Keskin DB; Carr SA; Wu CJ; Regev A
    Nat Biotechnol; 2022 Feb; 40(2):209-217. PubMed ID: 34663921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
    Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
    Elife; 2020 Apr; 9():. PubMed ID: 32314731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
    Chikata T; Paes W; Akahoshi T; Partridge T; Murakoshi H; Gatanaga H; Ternette N; Oka S; Borrow P; Takiguchi M
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31217245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
    Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins.
    Othoum G; Maher CA
    NAR Cancer; 2023 Jun; 5(2):zcad024. PubMed ID: 37275273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.
    de Beijer MTA; Jansen DTSL; Dou Y; van Esch WJE; Mok JY; Maas MJP; Brasser G; de Man RA; Woltman AM; Buschow SI
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31852786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.
    Kumari S; Wälchli S; Fallang LE; Yang W; Lund-Johansen F; Schumacher TN; Olweus J
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):403-8. PubMed ID: 24344295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability.
    Cleyle J; Hardy MP; Minati R; Courcelles M; Durette C; Lanoix J; Laverdure JP; Vincent K; Perreault C; Thibault P
    Mol Cell Proteomics; 2022 May; 21(5):100228. PubMed ID: 35367648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.
    Chikata T; Paes W; Kuse N; Partridge T; Gatanaga H; Zhang Y; Kuroki K; Maenaka K; Ternette N; Oka S; Borrow P; Takiguchi M
    J Virol; 2022 May; 96(10):e0043222. PubMed ID: 35475667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy.
    Wang M; Yin B; Matsueda S; Deng L; Li Y; Zhao W; Zou J; Li Q; Loo C; Wang RF; Wang HY
    PLoS One; 2013; 8(2):e56730. PubMed ID: 23437226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.